43North — Oncolinx

Oncolinx

We make the next generation of cancer therapies.

We make the next generation of cancer therapies.

INDUSTRY

Life Sciences

FROM

Boston, MA

ABOUT

Oncolinx, in conjunction with the National Cancer Institute, is developing antibody-drug conjugates (ADCs) that carry a patented, immune-activating drug payload called Azonafide exclusively to cancer cells. The Oncolinx platform is partnered with more than 14 leading pharmaceutical companies and 6 academic labs all over the world – concurrently developing ADCs across 30 different cancer indications.

WATCH

CEO

Sourav Sinha

CEO